Fukuda Denshi Co (FKDSF) Fair Value & Analysis
Healthcare · US · Market cap $1.1B
Fukuda Denshi Co
FKDSF · US
Fair value as of: Jul 24, 2026
From 22 valuation models · updated 17 days ago
Fair value updated Jul 24, 2026, revised from $85.29 to $83.92 (−1.6%) since Jun 25, 2026.
A solid business, screening 97% undervalued on our models.
What matters now
- The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case ($61.87). The market is more pessimistic than our downside scenario.
Price vs Fair Value (4 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 24, 2026.
How to read this chart
4‑month range $42.55 – $42.55 · fair‑value band $61.87 – $105.02 · the $42.55 price screens below the $83.92 fair value. As of Jul 24, 2026.
Analysis
Fukuda Denshi Co (FKDSF) currently trades at $42.55, while our model-based Fair Value estimate is $83.92, implying the stock looks roughly 97.2% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Fukuda Denshi Co generated revenue of $140B at a net margin of 13.5%. Revenue grew 3.1% year over year. It earns a return on equity of 10.1%. The stock trades on a trailing P/E of 10.1. Fundamentals as of Jul 24, 2026
Our scenario range runs from $61.87 (bear case) to $105.02 (bull case); at $42.55, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 97%, FKDSF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Multiples ($87.06) versus Asset-Based ($28.48). Highest evidence: Growth DCF (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Fukuda Denshi Co., Ltd. engages in the manufacture and sale of medical instruments in Japan and internationally. The company offers resting electrocardiograph and stress test products; patient monitoring systems, including central and bedside monitors, transmitters, and central viewer workstations; and vascular screening systems, such as data management …
Full company description
Fukuda Denshi Co., Ltd. engages in the manufacture and sale of medical instruments in Japan and internationally. The company offers resting electrocardiograph and stress test products; patient monitoring systems, including central and bedside monitors, transmitters, and central viewer workstations; and vascular screening systems, such as data management software. Fukuda Denshi Co., Ltd. was founded in 1939 and is based in Tokyo, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
Fukuda Denshi Co reported revenue of $139B in FY2025 versus $135B in FY2023, a compound +1.6%/yr. Reported net income was $18.6B in FY2025, compounding +3.8%/yr from FY2023.
Watch FKDSF: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Fukuda Denshi Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fukuda Denshi Co (FKDSF) overvalued or undervalued?
What is the fair value of FKDSF?
What is the quality score of FKDSF?
What is the revenue of Fukuda Denshi Co (FKDSF)?
What is the net profit margin of FKDSF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Fukuda Denshi Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.